The addition of CD38 monoclonal antibody to triplet regimens improves survival in newly diagnosed multiple myeloma with high-risk cytogenetics: a systematic review and meta-analysis of randomized controlled trials.

ABSTRACT:

Background

The efficacy of CD38 monoclonal antibody (mAb)-based quadruplet regimens versus triplet regimens in newly diagnosed multiple myeloma (NDMM) patients with high-risk cytogenetics remains controversial. This meta-analysis aims to consolidate evidence from randomized controlled trials (RCTs) to resolve this clinical uncertainty.

Methods

We systematically searched PubMed, EMBASE, and the Cochrane Library for RCTs comparing CD38 mAb-based quadruplet regimens with triplet regimens in NDMM patients with high-risk cytogenetics. The primary outcomes were the rate of minimal residual disease (MRD) negativity at a sensitivity of 10^-5 and progression-free survival (PFS).

Results

Nine RCTs comprising 4557 patients were included. Compared to triplet regimens, C

SUBMITTER: Hu B 

PROVIDER: S-EPMC12816236 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature